Sign in to fuzzto save your conversations, follow your research and come back anytime.
Anthem Biosciences
ANTHEM
NSE
BSE
NSEBSESectorHealthcare
950.70
Loading chart…
NSEBSECompany insights, generated from the most recent coverage.
FY26 full-year PAT grew 31.1% YoY to ₹5,918 Mn with EBITDA margin expanding to 43.4%, demonstrating strong operating leverage.
Q1 FY27 revenue dip of 22.6% attributed to customer delivery timing shifts rather than demand weakness; management expects growth from Q2 onwards.
Over 80% order-book visibility for targeted CRDMO sales in FY27 provides high earnings certainty despite Q1 volatility.
